# Merck

Type: Company (MRK)

Source: GetYourBrief — https://getyourbrief.com/entity/merck
Canonical HTML page: https://getyourbrief.com/entity/merck

## Timeline

- **2028**: Keytruda Patent Expiration — The primary patent for Merck's blockbuster drug Keytruda expires, opening the door for biosimilars.
- **2028**: Keytruda Patent Expiry — Merck faces biosimilar competition for its top-selling immunotherapy drug.
- **2028-01-01**: Keytruda Patent Cliff — Expected loss of exclusivity for Merck's top-selling cancer drug, Keytruda.
- **2027**: NXT 41X Launch — Anticipated commercial launch of Elutia's next-gen drug-eluting biomaterial.
- **2027**: Pipeline Integration — Merck integrates Terns' small-molecule oncology candidates into its global R&D infrastructure.
- **2027**: TERN-701 Data Readout — Key clinical milestones for the leukemia candidate are expected to drive valuation.
- **2026-Q4**: Expected Closing — Anticipated completion of the acquisition following regulatory and shareholder approvals.
- **2026-07-16**: FDA Approves Lipfendra — The FDA approved Lipfendra (enlicitide), the first once-daily oral PCSK9 inhibitor, for adults with hypercholesterolemia including inherited forms, based on Phase 3 CORALreef trials showing 56-59% LDL-C reduction.
- **2026-Q3**: Expected Closing — The deal is anticipated to close following regulatory approvals and Terns shareholder vote.
- **2026-Q2**: Bumble 2.0 Launch — Targeted launch of AI-enabled platform experience.
- **2026-03-25**: Acquisition Announced — Merck and Terns Pharmaceuticals announce a definitive $6.7 billion merger agreement.
- **2026-03-25**: Acquisition Announced — Merck and Terns Pharmaceuticals sign a definitive agreement for a $6.7B buyout.
- **2026-03-25**: Terns Acquisition Announced — Merck agrees to buy Terns Pharmaceuticals for $6.7 billion to acquire TERN-701.
- **2026-03-24**: Analyst Sentiment Review — Major firms maintain ratings, citing steady execution of the strategic pivot.
- **2026-03-24**: Sentiment Review — Major analysts maintain existing price targets and ratings despite the earnings beat.

## Recent coverage (16 stories, network-wide)

### Healthcare +2.9% to Record, S&P +0.21% as Yields Ease
2026-08-20 00:48:31 · Sector: finance · Sentiment: Strongly positive · Impact: 8/10 · Sources: 4

For finance readers, Aug. 19 was a case study in cross-asset relief: Treasury buyback news pulled the 30-year yield off its highest since 2007, feeding a 0.21% S&P 500 gain, while a more than 137% Moderna surge drove healthcare to a record 2.9% gain. The support for risk appetite masks a hawkish Fed minutes message and an unresolved long-term rate threat to AI-heavy valuations.
Full story: https://getfinancebrief.com/story/finance-markets-healthcare-record-yields-ease

### Moderna 177% Surge Lifts S&P 500 Healthcare Sector 2.9% to Record
2026-08-20 00:37:19 · Sector: health · Sentiment: Strongly positive · Impact: 8/10 · Sources: 4

Moderna's mRNA cancer therapy readout sent its shares up as much as 177%, driving a 2.9% record gain in the S&P 500 healthcare sector amid easing Treasury yields. The rally lifted peers including Merck, BioNTech and Novavax, but macro rate worries persist.
Full story: https://gethealthbrief.com/story/moderna-177-pct-healthcare-sector-record

### New pill cuts LDL 59%: How Lipfendra could change cholesterol care for millions
2026-07-16 22:00:46 · Sector: health · Sentiment: Strongly positive · Impact: 9/10 · Sources: 132

The FDA approved the first oral PCSK9 inhibitor, Lipfendra, demonstrating a 59% LDL reduction in trials. The pill form removes injection barriers and is priced lower than existing injectables, potentially improving adherence and access for patients with high cholesterol.
Full story: https://gethealthbrief.com/story/lipfendra-oral-pcsk9-lowers-ldl-59-percent-patient-access

### Merck’s oral PCSK9 inhibitor hits 59% LDL cut, leapfrogging injectable rivals
2026-07-16 22:00:10 · Sector: bio · Sentiment: Strongly positive · Impact: 9/10 · Sources: 132

Merck won FDA approval for Lipfendra, a small-molecule oral PCSK9 inhibitor that achieved 56-59% LDL-C reductions in Phase 3. This breakthrough in oral delivery challenges the dominance of injectable biologics from Amgen and Sanofi/Regeneron.
Full story: https://getbiobrief.com/story/merck-lipfendra-fda-approval-oral-pcsk9-59-percent

### Merck Strikes $6.7B Terns Acquisition to Counter Keytruda Patent Cliff
2026-03-25 19:20:53 · Sector: startups · Sentiment: Positive · Impact: 8/10 · Sources: 2

Merck has agreed to acquire Terns Pharmaceuticals for $6.7 billion, securing a late-stage leukemia candidate to diversify its oncology portfolio. The deal provides Merck with TERN-701, a promising treatment for chronic myeloid leukemia, as it prepares for the 2028 patent expiration of its blockbuster drug Keytruda.
Full story: https://getstartupbrief.com/story/merck-acquires-terns-pharmaceuticals-6-7b

### Merck to Acquire Terns Pharmaceuticals for $6.7B to Bolster Oncology Pipeline
2026-03-25 19:18:13 · Sector: bio · Sentiment: Positive · Impact: 8/10 · Sources: 2

Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, securing a promising allosteric BCR-ABL inhibitor for leukemia. The deal is a strategic move to diversify Merck's oncology portfolio as it prepares for the 2028 patent expiration of its blockbuster drug, Keytruda.
Full story: https://getbiobrief.com/story/merck-terns-pharmaceuticals-acquisition-6-7b

### Merck Acquires Terns for $6.7B to Hedge Against Keytruda Patent Cliff
2026-03-25 16:35:43 · Sector: finance · Sentiment: Positive · Impact: 8/10 · Sources: 2

Merck has agreed to acquire Terns Pharmaceuticals for $6.7 billion in cash to bolster its oncology pipeline ahead of the 2028 patent expiration for its blockbuster drug, Keytruda. The deal centers on TERN-701, a promising leukemia treatment that positions Merck to compete directly with established players like Novartis.
Full story: https://getfinancebrief.com/story/merck-terns-acquisition-oncology-pipeline

### Merck to Acquire Terns for $6.7B to Mitigate Keytruda Patent Cliff
2026-03-25 16:35:08 · Sector: bio · Sentiment: Positive · Impact: 8/10 · Sources: 2

Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion in cash, a strategic move to diversify its oncology pipeline. The deal centers on Terns' promising leukemia candidate, TERN-701, as Merck prepares for the 2028 patent expiration of its blockbuster immunotherapy, Keytruda.
Full story: https://getbiobrief.com/story/merck-terns-acquisition-oncology-strategy

### Merck to Acquire Terns for $6.7B to Fortify Oncology Pipeline
2026-03-25 16:34:35 · Sector: health · Sentiment: Positive · Impact: 8/10 · Sources: 2

Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, a strategic move designed to diversify its oncology portfolio. The acquisition comes as Merck prepares for the impending patent expiration of its top-selling cancer immunotherapy, Keytruda, later this decade.
Full story: https://gethealthbrief.com/story/merck-terns-acquisition-oncology-strategy

### Codexis Holds Steady as ECO Synthesis Gains Traction Post-Q4 Earnings Beat
2026-03-24 23:00:38 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Codexis reported a significant Q4 2025 earnings beat, driven by its ECO Synthesis platform and expanding CDMO partnerships. Despite a raised 2026 revenue outlook and a surprise GAAP profit, analyst sentiment remains largely unchanged as the market awaits further commercial validation of its RNA manufacturing technology.
Full story: https://getfinancebrief.com/story/codexis-cdxs-earnings-analyst-sentiment-analysis

### Codexis Sustains Analyst Confidence Following Q4 Beat and 2026 Revenue Guidance
2026-03-24 23:00:34 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Codexis (CDXS) has maintained steady analyst sentiment following a strong Q4 2025 performance that exceeded revenue and earnings expectations. The company’s strategic pivot toward its ECO Synthesis platform for RNA manufacturing is gaining commercial traction, supported by a 2026 revenue target of $72M–$76M.
Full story: https://getbiobrief.com/story/codexis-cdxs-earnings-analyst-sentiment-2026

### Wall Street Zen Upgrades Codexis and Enovis on Strong 2026 Growth Outlooks
2026-03-16 06:31:28 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wall Street Zen has upgraded the stock ratings for Codexis (CDXS) and Enovis (ENOV), signaling increased confidence in their long-term strategic pivots. The upgrades follow robust quarterly performances and the unveiling of ambitious 2026 revenue targets driven by high-margin technological innovations.
Full story: https://getbiobrief.com/story/codexis-enovis-stock-upgrades-wall-street-zen

### Biotech Sector Pivots: Codexis, Elutia, and Biote Signal Strategic Shifts
2026-03-12 00:14:38 · Sector: bio · Sentiment: Positive · Impact: 6/10 · Sources: 9

Q4 2025 earnings for specialized biotech firms reveal a sector-wide shift toward high-margin manufacturing and strategic divestitures. While Codexis capitalizes on its Merck partnership and ECOsynthesis platform, Elutia has cleared its debt through an $88 million divestiture to Boston Scientific.
Full story: https://getbiobrief.com/story/biotech-q4-2025-earnings-strategic-pivots

### MedTech and Life Sciences Pivot Toward AI Efficiency and Asset Optimization
2026-03-12 00:13:28 · Sector: health · Sentiment: Positive · Impact: 6/10 · Sources: 9

The Q4 2025 earnings cycle for mid-cap healthcare and life sciences firms reveals a strategic shift toward high-margin AI integration and portfolio streamlining. Companies like Elutia and Codexis are leveraging divestitures and technology transfers to shore up balance sheets, while AI-driven productivity gains are becoming a primary differentiator in clinical and operational workflows.
Full story: https://gethealthbrief.com/story/medtech-life-sciences-ai-efficiency-asset-optimization

### Merck and Mayo Clinic Forge AI Alliance for Precision Medicine
2026-02-19 11:28:02 · Sector: ai · Sentiment: Positive · Impact: 8/10 · Sources: 2

Merck and Mayo Clinic have launched a strategic R&D collaboration to integrate artificial intelligence into drug discovery and precision medicine. The partnership combines Mayo Clinic's vast clinical data with Merck's therapeutic expertise to identify novel drug targets and personalize patient care.
Full story: https://getaibrief.com/story/merck-mayo-clinic-ai-precision-medicine-partnership

### Merck and Mayo Clinic Launch AI-Driven Drug Discovery Collaboration
2026-02-19 11:27:00 · Sector: bio · Sentiment: Positive · Impact: 8/10 · Sources: 2

Merck and Mayo Clinic have entered a multi-year research and development collaboration to leverage artificial intelligence for drug discovery and personalized patient care. The partnership integrates Merck's pharmaceutical expertise with Mayo Clinic's clinical data and AI capabilities to accelerate the development of targeted therapies.
Full story: https://getbiobrief.com/story/merck-mayo-clinic-ai-drug-discovery-partnership

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.